Observational studyAnnals of clinical and translational neurology2025
Long-Term Survival, Burden of Disease, and Patient-Centered Outcomes in Maximally Treated Intracerebral Hemorrhage.
Observational study in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03183167 (Universitätsklinikum Erlangen Cohort of Patients With Spontaneous Intracerebral Hemorrhage), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Universitätsklinikum Erlangen Cohort of Patients With Spontaneous Intracerebral Hemorrhage
Who cites it
2 citing papers in PubMed.
- Functional outcome, five-year survival and burden of disease after size- and location-matched hemorrhagic versus ischemic stroke.Neurological research and practice · 2026Article
- Predicting long-term mortality in spontaneous intracerebral hemorrhage patients using the advanced lung cancer inflammation index.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIncreasing evidence shows that patients with intracerebral hemorrhage (ICH) can achieve better-than-expected outcomes with aggressive therapy. However, real-world long-term data, patient-centered outcomes, and societal measures after maximal ICH treatment are lacking. This study aimed to analyze 5-year survival, utility-weighted functional outcomes, and burden of disease in maximally treated ICH patients, stratified by max-ICH Score.
methodsThis study investigated consecutive patients with spontaneous ICH included in the single-center Longitudinal Cohort Study on ICH Care (UKER-ICH, NCT03183167, 2006-2015). We included all patients without early care limitations, hereinafter referred to as maximally treated. We analyzed the stratification by max-ICH Score of cumulative 5-year survival using Kaplan-Meier estimates and COX regression modeling, disease burden using disability-adjusted life years (DALYs), and patient-centered outcome at 12 months using the Utility-Weighted modified Rankin Scale (UW-mRS).
resultsThe 5-year survival rate of the included 1022 maximally treated patients was 53%, stratified by max-ICH Score (0 points: 85%, 1: 91%, 2: 69%, 3: 59%, 4: 47%, 5: 32%, 6: 29%, 7: 18%, ≥ 8: 0%, log-rank p < 0.001). The mean number of DALYs was 8.94 (±8.15, standard deviation [SD]), consisting of 4.27 years of life lost (±7.79, SD) and 4.67 years lived with disability (±6.38, SD). Patients with a max-ICH Score of 5 had the highest burden of disease (12.76 [±9.43, SD]). The mean UW-mRS at 12 months was 0.45 (±0.37, SD) and decreased with increasing max-ICH Score (0: 0.80 [±0.23], 1: 0.73 [±0.29], 2: 0.67 [±0.29], 3: 0.50 [±0.34], 4: 0.39 [±0.34], 5: 0.25 [±0.30], 6: 0.19 [±0.28], 7: 0.16 [±0.26], ≥ 8: 0.08 [±0.22], p < 0.001).
interpretationThese observational data, stratified by max-ICH Score, provide patients and treating physicians with an initial severity assessment in terms of potential long-term patient-centered outcomes and burden of disease following maximal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.